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PTENWhile accumulating evidence demonstrates the existence of prostate cancer stem cells (PCSCs), PCSCs have
not been isolated and thoroughly characterized. We report here the enrichment and characterization of
sphere-propagating cells with stem-like properties from DU145 PC cells in a deﬁned serum-free medium
(SFM). Approximately 1.25% of monolayer DU145 cells formed spheres in SFM and 26% of sphere cells formed
secondary spheres. Spheres are enriched for cells expressing prostate basal and luminal cytokeratins (34βE12
and CK18) and for cancer stem cell markers, including CD44, CD24, and integrinα2β1. Upon culturing spheres
under differentiating media conditions in the presence of 10% serum, cells positive for CD44 and CD24 were
substantially reduced. Furthermore, spheres could be generated from the sphere-derived adherent cell
cultures and xenograft tumors, demonstrating the stemness of DU145 spheres. We have maintained spheres
for more than 30 passages within 1.5 years without noticeable loss of their “stemness”. Sphere cells possess
self-renewal capacity, display signiﬁcant increases in proliferation potential, and initiate xenograft tumors
with enhanced capacity compared to monolayer DU145 cells. While EGF promoted the generation and
maintenance of these stem-like cells, bFGF inhibited these events. Sphere cells proliferate slowly with a
signiﬁcant reduction in the activation of the PI3K-AKT pathway compared to monolayer DU145 cells. While
knockdown of PTEN enhanced AKT activation, this did not affect the generation of primary spheres and the
propagation of secondary spheres. Consistent with this observation, we were able to demonstrate the
generation and propagation of spheres without the addition of external growth factors. This article is part of a
Special Issue entitled: 11th European Symposium on Calcium.opean Symposium on Calcium.
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Prostate cancer (PC) is themost common cancer affectingmen and
the second leading cause of cancer-related deaths in males in the
developed world [1,2]. The disease progresses from intra-epithelial
neoplasia or de novo, locally invasive carcinoma to metastatic cancer
that advances to hormone refractory prostate cancers (HRPCs). HRPCs
contribute virtually to all PC associated deaths [3,4]. Although the
exact mechanisms responsible for PC initiation and progression
remain elusive, PCSCs are widely regarded to be the origin of PC
initiation and progression [5–7].
Several lines of evidence suggest the existence of PCSCs. A small
population of primary PC cells expressing the surface antigenic proﬁle
CD44+α2β1hiCD133+ was suggested to be a candidate for PCSCs [8].This possibility is supported by several reports. Cancer stem cells are
known to share similar surface antigens with their tissue stem cell
counterparts [9–13]. Consistentwith this concept, humanα2β1hiCD133+
prostate epithelial cells possess the properties of prostate stem cells
[14], and a single cell in the mouse prostate deﬁned as Lin-Sca-1+
CD133+CD44+CD117+ is capable of generating an intact prostate
[15]. Additionally, primary human prostate epithelial cells and ma-
lignant cells that ectopically express human telomerase reverse tran-
scriptase (hTERT) displayed the CD44+α2β1hiCD133+ surface proﬁle
[16–18]. Furthermore, hTERT-transformed primary prostate epithelial
cells derived from a patient with advanced PC were able to generate
prostate tumors that resembled the original tumor [17]. These
observations are consistent with a report that CD44+ subpopulations
isolated from several cultured PC cell lines were more tumorigenic in
nude mice than the isogenic CD44- population [19]. However, despite
these observations supporting the candidacy of CD44+α2β1hiCD133+
cells as PCSCs, it remains to be demonstrated whether CD44+α2β1hi
CD133+ cells isolated from primary PC tissues are capable of initiating
tumors in immuno-compromised mice. Therefore, to date, bona-ﬁde
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to the challenging nature of PC tissue, limited access to clinical samples,
highly heterogeneous PC materials, and frequent inﬁltration into
surrounding non-neoplastic prostatic tissue.
Although in vitro PC cells with the properties of cancer stem cells
(CSC) have been studied, these cells have not been thoroughly
investigated. Different systems have been used to culture PCSCs,
including using suspension, low adherence culture on a layer of agar
[16,18], or use of low adherence plates [17,20]. In general, two types of
media are used to culture these stem-like PC cells that contained either
fetal bovine serum (FBS) [17,19], or supplemented with epidermal
growth factor (EGF; 10 or 20 ng/ml) and basic ﬁbroblast growth factor
(bFGF; 10 or 20 ng/ml) [16,20]. Although these stem-like PC cells have
been demonstrated to have CSC properties, these cells have not been
cultured for an extended period of time. Therefore, whether these cells
constituted asprogenitors or bona-ﬁdePCSCs remains to bedetermined.
Furthermore, the essential pathways that regulate PCSCs have not been
examined until very recently. Dubrovska and colleagues recently
reported that the PI3K-AKT pathway is activated, which is required for
isolation and maintenance of DU145-derived PCSCs [20].
We have characterized a sub-population of DU145 cells that
propagate as spheres under deﬁned serum-free conditions and which
display stem-like properties. Approximately 1.25% of DU145 mono-
layer cells are able to form spheres in a serum-free medium
supplemented with EGF (10 ng/ml). Spheres are enriched in sphere-
forming cells, since approximately 26% of sphere-derived cells are
capable of forming secondary spheres. bFGF inhibits the formation of
primary spheres and the propagation of secondary spheres. Although
EGF signiﬁcantly promotes the generation and propagation of
spheres, these stem-like cells are able to form spheres without
external EGF. DU145 sphere cells initiated xenograft tumors with
increased ability compared to monolayer cells. Unlike a recent report,
the PI3K-AKT pathway does not play a major role in the generation
and maintenance of DU145 spheres.
2. Materials and methods
2.1. Tissue cultures and knockdown of PTEN
DU145 prostate cancer cells, 293 T, Caco-2 and PC12 cells were
obtained from ATCC, and were cultured and maintained according to
ATCC instructions.
Short-hairpin PTEN targeting (shPTEN) vector was constructed by
inserting the PTEN targeting sequence (GTATAGAGCGTGCAGATAA)
into the pRIH retroviral vector as a hairpin, according to our published
conditions [21]. High titres of pRIH (empty vector: EV) and pRIH/
shPTEN were produced using 293 T cell as described previously [21].
DU145 cells were subsequently infectedwith EV or shPTEN retrovirus.
Infected cells were selected in hygromycin (0.5 mg/ml) and then
examined for PTEN expression using western blot.
2.2. Isolation and propagation of PCSC
DU145 monolayer cells were enzymatically-dissociated in trypsin
(0.25%)/EDTA and resuspended at clonal (10 cell/μl) or sub-clonal
density in a serum-free medium (DMEM/F12; 3:1 mixture) contain-
ing 0.4% BSA, 0.2×B27 lacking Vitamin A (Invitrogen) and supple-
mented with recombinant EGF at 10 ng/ml (Sigma-Aldrich). When
examining the effect of bFGF on sphere formation, recombinant bFGF
(Invitrogen) was added at a concentration of 10 ng/ml, in addition to
heparin at 4 μg/ml (Sigma-Aldrich). Typical spheres formed in 10 to
12 days. Sphere cells were sub-cultured using trypsin and then
resuspended in the above medium at clonal density.
To examine the sphere forming capacity of DU145monolayer cells,
cells from sub-conﬂuent (~80%) cultures were resuspended in the
above SFM at a density 5×103 or 104 cells/ml, followed by dispensing1 mL of this cell suspension into individual wells of a 24-well culture
plate (4 wells per treatment). The number of spheres that formed
after 12 days of culture was counted. To assay the sphere forming
capacity of secondary or established spheres, sphere cells were
individualized by trypsinization and plated in 96-well plates at a
density of 1 cell/well (120 wells in total). Wells containing only single
cells were monitored. The number of spheres that formed was
counted after 12 days of culture. Triplicate experiments were
conducted. Experiments were repeated three times.
2.3. Anchorage-Independent Growth Assay
DU145 monolayer and sphere cell cultures were plated in
individual wells of six-well plates at a density of 104 cell/well in
1.5 mL of media containing 0.25% agarose. Each treatment was
conducted in triplicate wells. After 8 weeks, colonies were counted
under a phase-contrast microscope in 5 random ﬁelds per well. Digital
images of plates were taken using a Sony Cybershot® (DSC-N2)
camera, and mean colony area (pixels) was determined using
ImagePro Plus 5.0 software. Duplicate experiments were conducted.
2.4. Cell Proliferation assay
DU145 monolayer cells and sphere cells were seeded in triplicate
in a 96-well plate at clonal density. Cell number was measured using
Roche Cell Proliferation kit 1 (MTT) according to the manufacturer's
instructions.
2.5. Western blot analysis
Preparation of cell lysates and performance of western blotting
were carried out according to our published procedure [22].
Antibodies used were goat anti-AKT (Santa Cruz, C-20, 1:1000),
rabbit anti-phospho-AKT (AKT-P; Ser473 phosphorylation) (Cell
Signaling, 1:1000), mouse anti-PTEN (Santa Cruz, clone A2B1,
1:500) and goat anti-β-actin (Santa Cruz, C-11, 1:1000). Densitomet-
ric analysis of bands was conducted using Scion Image software.
2.6. Immunoﬂuorescence and Immunohistochemistry
Immunoﬂuorescent (IF) staining of monolayer cell cultures was
performed by ﬁxing cells with 4% paraformaldehyde (20 min) or
methanol:acetone (3:7) solution for 10 min, followed by stainingwith
the speciﬁed primary antibodies. For spheres, intact spheres were
ﬁxed, washed three times with PBS and allowed to settle in a 30%
sucrose solution overnight at 4 °C. Sucrose solution was removed and
intact spheres were added to embedding medium for frozen tissue
sections (Sakura Tissue-Tek O.C.T. compound). Frozen sections (4 μm)
were prepared, and IF staining was carried out using the following
antibodies: rabbit polyclonal anti-p16INK4A (Santa Cruz, C-20, 4 μg/
ml), rabbit polyclonal anti-BMI1 (Santa Cruz, H-99, 4 μg/ml), mouse
anti-CD133/1 (Miltenyi Biotec, clone AC133, 5ug/ml), mouse anti-
human CD44 (BD Biosciences, clone G44-26, 2 μg/ml), mouse anti-
CD24 (Neomarkers, clone SN3, 2 μg/ml), mouse anti-cytokeratin 18
(CK18; Santa Cruz, clone DC-10, 2 μg/ml), mouse anti-integrin α2β1
(Chemicon, clone BHA2.1, 0.5 μg/ml), mouse anti-human cytokeratin
HMW (DakoCytomation, clone 34βE12, 1 μg/ml), mouse anti-Synap-
tophysin (Millipore, clone SVP-38, 1:100). IgG was used as a negative
control. Slides were subsequently washed in 1×PBS and then
incubated with secondary antibodies (donkey anti-mouse IgG-FITC
or donkey anti-mouse IgG-PE, 1:200 dilution; Jackson Laboratories)
for 1 hour. Slides were mounted with a coverslip using Vectashield
Mounting Mediumwith DAPI (Vector Laboratories, Inc., H-1200), and
images were captured using a Zeiss Axiovert 200 M inverted
ﬂuorescence microscope using AxioVision 3.1 software. Images were
processed using CorelDraw 14.
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tissues were sectioned at 3 μm thickness, deparafﬁnized, rehydrated,
subjected to antigen retrieval and endogenous peroxidase quenching
as indicated for immunohistochemistry (IHC) staining. Sections were
blocked for 1 hour at room temperature in 3% goat serum and 3% BSA
in TBST, followed by overnight incubation at 4 °C with rabbit anti-
human CD44 (Abcam, ab51037, 1:100) and mouse anti-human
cytokeratin HMW (Dako, clone 34βE12) antibodies. Slides were
subsequently washed in PBS and then incubated with secondary
antibodies (goat anti-rabbit IgG Alexa Fluor 594 and goat anti-mouse
IgG Alexa Fluor 488, 1:200; Invitrogen) for 1 hour. Sections were
counterstained with DAPI.
IHC staining of the DU145 xenografts was performed as described
previously [34]. Brieﬂy, sectioned slides were deparafﬁnized, antigen
retrieval was performed and sections were incubated with the
following primary antibodies: anti-Chromogranin A (Dako, clone
DAK-A3, 1:100), anti-human cytokeratin HMW (Dako, clone 34βE12,
1:100), anti-CK18 (Santa Cruz, clone DC-10, 1:100), anti-E-cadherin
(Dako, clone NCH-38, 1:200), and anti–Synaptophysin (Dako, clone
SY38, 1:25). Biotinylated goat anti-mouse IgG and avidin-biotin
complex (ABC) were then added (Vectastain ABC kit, Vector
Laboratories). The chromogen reaction was carried out with diami-
nobenzidine, and counterstainingwas donewith hematoxylin. Images
were captured using an Olympus BX41 light microscope.
2.7. RNA extraction and Reverse Transcriptase–PCR (RT-PCR)
RNA was extracted from cells using Trizol Reagent (Invitrogen)
according to the manufacturer's instructions. RT-PCR was carried out
using SuperScript III reverse transcriptase (Invitrogen) and the
designed primers. β-Actin was used as an internal control. Primers
and RT-PCR conditions are listed in Supplementary Table 1.
2.8. Xenograft tumor formation
DU145 monolayer and sphere cells were resuspended in MEM/
Matrigel mixture (1:1 volume), followed by implantation of 0.1 ml of
this mixture subcutaneously (s.c.) into ﬂanks of 8-week-old male
NOD/SCID mice (The Jackson Laboratory). Mice were inspected for
tumor appearance, by observation and palpation, and tumor growth
was measured weekly using a caliper. Tumor volume was determined
using the standard formula: L×W2×0.52, where L and W are the
longest and shortest diameters, respectively. The presence of each
tumor nodule was conﬁrmed by necropsy. All animal work was
carried out according to experimental protocols approved by the
McMaster University Animal Research Ethics Board.
2.9. Statistical analysis
Statistical analysis was performed using SPSS 10.0 for Windows
software. Data were presented as mean±SE (standard error) unless
otherwise speciﬁed. All Student's t-tests performed were two-tailed.
A p-valueb0.05 was considered statistically signiﬁcant.
3. Results
3.1. Generation and propagation of DU145 sphere cells
A variety of evidence suggests that human prostate stem cells
reside in the basal cell layer of the human prostate [23,24] and basal
cells express the EGF receptor [25]. Based on this knowledge, we
formulated a medium composed of DMEM/F12 (3:1), 0.4% BSA, 0.2×
B27 supplemented with EGF at 5, 10, or 20 ng/ml and examined their
ability to support the growth of DU145 stem-like cells as suspension
spheres. Supplementation of 10 ng/ml of recombinant EGF to the
serum-free medium (SFM+EGF) was sufﬁcient to support DU145cells to grow as spheres (Fig. 1A). Individual spheres were most likely
derived from single cells, as spheres were formed at clonal (10 cells/
μl) density (Fig. 1A). Neural spheres were routinely generated at the
densities of 10 or 50 cell/μl [26] and at 10 cells/μl, neural spheres have
been shown to derive from single cell [27]. Approximately 1.25% of
DU145 monolayer cells are able to form primary spheres (Fig. 1C) and
spheres contain an average of 100–150 cells (data not shown).
We subsequently examined whether DU145 sphere cells possess
self-renewal capacity using a well-established assay [28]. When
sphere cells were seeded at single cell/well in a 96-well plate, typical
spheres were formed during the course of 12 days (Fig. 1B). In the
total of 360 single-cell wells (120 single-cell wells per experiment in
the total of three repeats) analyzed, 26.1±2% of sphere cells formed
subsequent spheres (Fig. 1C). This is consistent with 20% of neural
[28] and brain cancer [9] sphere cells being able to form new spheres.
Collectively, these observations suggest that DU145 spheres are
composed of a heterogeneous population of cells with (stem-like
cells) or without (progenitor cells) self-renewing capacity. In
comparison to monolayer cells, sphere cells display high levels of
proliferation potential when cultured in SFM+EGF (Fig. 1D). This is
consistent with the reported high level of proliferation potential
associated with brain cancer stem cells, when cultured in a deﬁned
serum-free medium [9].
3.2. DU145 sphere-propagating cells express stem cell factors, basal and
luminal epithelial cell markers
Transcriptional factors Nanog, Oct4 and Sox2 are known to express
in stem cells [29–31]. Consistent with this observation, DU145 sphere
cells express Nanog, Oct4, and Sox2 (Supplementary Fig. 1A). While
both Nanog and Oct4 were expressed at comparable levels in both
monolayer and sphere cells (Supplementary Fig. 1A), Sox2 expression
was enhanced in sphere cells (Supplementary Fig. 1A). BMI1 plays an
important role in the self-renewal of neuronal and haematopoetic
stem cells [32,33]. We have recently shown that BMI1 facilitates
prostate tumorigenesis [34], andmore recently it has been shown that
BMI1 is a critical regulator of murine adult prostate stem cell self-
renewal [35]. Consistent with these observations, BMI1was expressed
exclusively in the nuclei of sphere cells (Supplementary Fig. 1B).
Taken together, these observations support the concept that DU145
spheres contain cells with stem-like properties.
Consistent with the above observations, sphere cells also express
candidate cancer stem cell surface markers. PCSCs have been indicated
to be CD44+α2β1hiCD133+ [16–18]. CD24 is associated with several CSC
or cancer-initiating cells [36]. To determine the cell surface antigen
proﬁle of DU145 sphere cells, we examined the expression of CD44,
CD24, integrin α2β1, and CD133. While the majority of sphere cells are
positive for CD44, CD24, and integrin α2β1 (Fig. 2), we could not
convincingly demonstrate the AC133 epitope of CD133 in DU145
spheres (data not shown). Furthermore, in more than 20 primary PC
specimens examined with Gleason scores ranging from 6–8, we also
failed to detect CD133 using the AC133 antibody (data not shown). This
may not result from our staining procedure, as the AC133 antibody
clearly detected the AC133 epitope of CD133 in AC133-positive Caco-2
cells [37] (Supplementary Fig. 2). The difference between our
observation and that of others may be due to the limited speciﬁcity of
reagents used to detect AC133 (see Discussion for details).
As evidence indicates that prostate stem cells reside in the basal
layer of human prostate [23,24], we have investigated the expression
of prostate basal, luminal and neuroendocrine (NE) markers in DU145
spheres. Using immunoﬂuorescence, spheres were shown to be
immunoreactive for basal epithelial high molecular-weight cytoker-
atins (CKs; 34βE12) and the luminal CK18 (Fig. 2). No staining was
detected in DU145 spheres for the NE marker synaptophysin,
although the antibody clearly detected its expression in synaptophy-
sin-positive PC12 cells (Supplementary Fig. 3). Consistent with these
Fig. 1. Isolation and characterization of a stem-like cell population from DU145 cells. A) Stem-like cells can be cultured as suspension spheres. DU145 cells were cultured in SFM
[DMEM/F12 (3:1 mixture), 0.4% bovine serum albumin (BSA), 0.2× B-27 supplement lacking Vitamin A, 1% penicillin/ streptomycin (P/S) and 10 ng/ml EGF] in a 24-well tissue
culture plate for 12 days. Typical ﬂoating spheres formed were photographed (bright ﬁeld images) at 50× (left panel) and 200× magniﬁcations (right panel). B) Sphere cells possess
self-renewal capacity. Individual sphere cells were seeded at a density of 1 cell per well, which are capable of forming a single sphere in 12 days. C) The rate of generation of primary
and subsequent spheres frommonolayer cells and established spheres (N2 passages). Quantiﬁcation of primary sphere formation was carried out using 24-well plates (104 cells/well
seeded). Tomeasure self-renewal capacity, individualized sphere cells were plated in 96-well plates at a density of 1 cell per well. A total of 360 wells were counted for three repeats,
with 120 wells recorded per experiment. Data were presented as mean±SE. D) DU145 monolayer cells and spheres were enzymatically-dissociated and plated at a density of 103
cells/well (96-well plate) in triplicate. Using the MTT assay, cell proliferation capacity was determined after 0, 3, 5, 7, 10 and 12 days of incubation. Representative image of results
(mean±SE) conducted in three independent experiments. ⁎pb0.05 (two-tailed, independent t-test).
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nin A could not be detected in xenograft tumors that were derived
from either DU145 monolayer cells or spheres, while epithelial
marker E-cadherin and prostate lineage-speciﬁc markers 34βE12 and
CK18 were detected (Supplementary Fig. 4).
3.3. DU145 spheres exhibit “stemness”
A typical character of SCs and CSCs is their ability to re-populate
the original heterogeneous population of cells and from these cells,
CSCs can be re-isolated. To demonstrate this property, we found that
sphere cells were able to proliferate asmonolayer cells in serum (10%)
containing medium and furthermore, spheres can be re-generated
from sphere-derived adherent cells (SDACs) in SFM+EGF medium.
To characterize this process, we have cultured SDACs to passage 20and analyzed the abilities of SDACs at different passages to form
spheres. When 103 SDACs were seeded in a 24-well plate at 1 cell/μl,
approximately 20% of SDACs formed spheres at passages 0 through 4
and the sphere-forming ability of SDACs signiﬁcantly declined after
passage 4 (Fig. 3A). At passage 20, approximately 2% of SDACs were
able to form spheres (Fig. 3A) in comparison to 1.25% of monolayer
cells being able to form spheres (Fig. 1C). Therefore, at least 20
passages are required for SDACs to resume a similar sphere-forming
frequency as the monolayer cell culture. Furthermore, from these
“differentiated” cell populations, spheres could be regenerated and
the ability of sphere generation correlates with their degree of
differentiation – passage numbers cultured under differentiating
media conditions. More importantly, both monolayer and sphere cells
formed xenograft tumors in NOD/SCID mice and from these xenograft
tumors, spheres could be isolated (Fig. 3B).
Fig. 2. Spheres are positive for CD44, CD24, integrin α2β1, prostate basal cytokeratins (34βE12) and luminal cytokeratin (CK18). DU145 spheres were immunoﬂuorescently stained
with the indicated antibodies (see Materials and Methods for details). Nuclei were counter-stained with DAPI. Typical images are shown. Scale bars represent 50 μm.
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neous cell population based on the proﬁle of cell surface markers of
spheres, SDACs, and monolayer DU145 cells. While sphere cells are
largely positive for CD44, CD24, integrin α2β1, and CK18 (Fig. 2),
approximately 40% or less of monolayer cells express these markers
(Fig. 4, Supplementary Fig. 5A). In comparison to sphere cells
(Fig. 2), the SDACs at passage 4 expressed CD44 and CD24, CK18,and integrin α2β1 at substantially reduced levels (Fig. 4, Supple-
mentary Fig. 5B). It was surprising to notice that the passage 4
SDAC population consisted of signiﬁcantly reduced number of
CD44-positive or CD24-positive cells compared to the monolayer
cell population (Fig. 4, Supplementary Fig. 5A, B). Although the
underlying mechanisms for these observations are not clear, these
mechanisms may be speciﬁc for CD44 and CD24, as the passage 4
Fig. 3. Sphere cells are able to produce a heterogeneous cell population that can produce spheres. A) The sphere-forming capacity of sphere-derived adherent cells (SDACs). SDACs
were cultured in the presence of 10% serum for the indicated passages, at which time their sphere-forming ability was determined by seeding SDACs at 103 cells/ml per well in 24-
well plates with triplicate replicates. Passage 0 indicates that sphere cells were cultured in the presence of 10% serum for a few days, followed by examination of their sphere-forming
ability without passage. The percentages of sphere-forming cells for each passage are also indicated. Data is presented as mean±SE of three independent experiments [* pb0.01;
# pb0.05 (two-tailed, independent t-test)]. B) H&E staining of xenograft tumors generated from monolayer DU145 cells and sphere cells (top panel). Isolation of spheres was from
xenograft tumors derived from monolayer DU145 cells. Similar results were also obtained for sphere-derived xenograft tumors (data not shown). Scale bar represents 50 μm.
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cells than the monolayer cell population (Fig. 4). The passage 20
population of SDACs consists of increasing numbers of CD44-
positive or CD24-positive cells and reduced numbers of CK18-
positive or α2β1-positive cells (Fig. 4, Supplementary Fig. 5B, C).
These changes in general make the passage 20 SDACs more closely
resemble monolayer cells than the passage 4 SDACs.
Furthermore, the heterogeneity of the sphere-repopulated cell
population could also be demonstrated in xenograft tumors. In both
monolayer cell- and sphere cell-derived xenograft tumors, CD44 and
34βE12 were clearly heterogeneously expressed (Fig. 5A) in compar-
ison to the largely homogenously expression of both markers in
sphere cells (Fig. 2). Interestingly, sphere cell-derived xenograft
tumors contain more cells that are CD44+, 34βE12+ and CD44+
34βE12+ than monolayer cell-derived xenograft tumors (Fig. 5A, B)
(see Discussion about the signiﬁcance of this observation).3.4. bFGF attenuates the isolation and propagation of DU145 spheres
EGF was commonly used together with bFGF in culturing PCSCs
[16,20]. To examine whether bFGF would enhance the numbers of
spheres formed, we seeded DU145 monolayer cells in SFM supple-
mented with EGF, bFGF (10 ng/ml), or EGF+bFGF at clonal (10 cells/
μl) or sub-clonal (5 cells/μl) densities. Surprisingly, in comparison to
EGF, bFGF not only signiﬁcantly reduced primary spheres formed but
also signiﬁcantly inhibited EGF-mediated formation of primary
spheres (Fig. 6A). Similar effects were also observed in sphere
propagation (Fig. 6B).
A typical characteristic of malignant tumors is their autocrine
ability. Since CSCs are responsible for tumor initiation and progres-
sion, CSCs may be independent on external growth factors. To
investigate this possibility, we performed primary and secondary
sphere formation under SFM without addition of EGF or other growth
Fig. 4. Spheres are able to re-populate a heterogeneous cell population. Spheres were
cultured in complete medium (DMEM, 10% FBS) as a monolayer (adherent culture) for
4 and 20 passages (p4 and p20), respectively, followed by examination for the
expression of CD44, CD24, CK18 and integrin α2β1 expression in monolayer, p4 and
p20 sphere-derived adherent cells (for typical images, see Supplementary Fig. 5). The
percentages of positively-stained cells for CD44, CD24, CK18 and integrinα2β1markers
were derived from randomly counting a total of 103 cells/marker in 5 random ﬁelds.
Data are presented as mean±SE. ⁎pb0.05 (two-tailed, independent t-test).
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the number of primary and secondary spheres formed compared to
the EGF medium, spheres were capable of forming in the GF- mediumFig. 5. Sphere cell-derived xenograft tumors consist of heterogeneous cell populations. A) E
cell- and sphere cell-derived xenograft tumors. Detection of CD44 and 34βE12 was perfor
Typical images are shown. Scale bars represent 20 μm. B) The percentages of CD44+, 34βE12
random ﬁelds. Data are presented as mean±SE. ⁎pb0.001 (two-tailed, independent t-test)(Fig. 6A, B). To further consolidate these observations, we took
advantage that sphere-derived adherent cells (SDACs) possess a range
of sphere-generating capacities (Fig. 3A).When seeded at 103 cells/ml
per well (or 1 cell/μl) in a 24-well plate in GF free medium, SDACs
generated spheres, although at reduced levels, compared with the
addition of EGF (Fig. 6C). Similar to the observations obtained with
addition of EGF, the ability of SDACs to form spheres in GF free
medium inversely correlates with the length of time (passage)
cultured under differentiating media conditions (Fig. 6C). Collectively,
the above observations demonstrate that external EGF is not required
to support DU145 sphere cultures. Interestingly, when compared to
bFGF medium, GF- medium was superior in the propagation of
spheres (Fig. 6B). This provides additional evidence that bFGF inhibits
the generation and propagation of stem-like DU145 cells, which is
consistent with the fact that the basal cells of prostatic glands contain
SCs and express EGF receptor [25].
3.5. Sphere cells proliferate slowly with reduced activation of the
PI3K-AKT pathway
Stem cells are normally kept in a quiescent stage or proliferate
slowly in their niches. It is not clear whether cancer stem cells
including PSCSs retain this property. It has been reported that DU145
stem-like cells proliferate more actively than monolayer cells under
sphere-forming SFM supplemented with insulin (4 μg/ml), EGFxpression of CD44 and prostate basal cytokeratin marker 34βE12 in DU145 monolayer
med using anti-CD44 and 34βE12 antibodies. Nuclei were counter-stained with DAPI.
+ and CD44+34βE12+ cells were derived by randomly counting a total of 103 cells in 5
in comparison to monolayer-derived xenograft tumors.
Fig. 6. EGF, but not bFGF, contributes to the formation of DU145 spheres. A) Primary sphere formation. DU145monolayer cells were seeded at a density of 5×103 and 104 cells/ml per
well, respectively. Triplicate experiments were performed, with quadruplicate replicates in each experiment. # pb0.05 (For 5,000 cells/ml seeded, EGF group is statistically different
from the EGF+bFGF group; two-tailed, independent t-test). B) Secondary sphere formation. Primary DU145 sphere-derived cells were seeded at a density of 103 cells/ml per well,
with quadruplicate replicates for each growth condition. Data are presented as mean±SE. ⁎pb0.01; # pb0.05 (two-tailed, independent t-test). C) SDACs at the indicated passages
were seeded at a density of 103 cells/ml per well, with quadruplicate replicates for each growth condition. Triplicate experiments were performed. ⁎pb0.01 (two-tailed, independent
t-test).
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observation that when cultured in SFM containing only EGF (10 ng/
ml), sphere cells show enhanced proliferation potential (Fig. 1D).
Since approximately 26% of sphere cells are capable of generating
spheres in sphere-forming medium (Fig. 1C), the majority of sphere
cells may not actively proliferate, concordant with the proﬁle of
sphere cell proliferation in sphere-forming medium (Fig. 1D). Both
monolayer and sphere cells proliferate very slowly up to day 4 in
sphere-forming medium, but sphere cells begin to proliferate
robustly afterwards (Fig. 1D), which may be attributable to the
initiation of sphere formation. We therefore reasoned that complete
medium supplemented with 10% serum (CM) should be used to
compare the proliferation rates of monolayer and sphere cells, as
the majority of monolayer and sphere cells actively proliferate in
this medium.
To minimize potential differentiation of sphere cells, we examined
the proliferation of sphere cells immediately cultured in CM along
with monolayer DU145 cells (Fig. 7A). As expected, both sphere and
monolayer cells proliferate in CM (Fig. 7A). Monolayer cells exhibit
more robust proliferation than sphere cells (Fig. 7A). Furthermore,
monolayer cells reached amuch higher level of conﬂuent density than
sphere cells (Fig. 7A). Taken together, these observations reveal that
sphere cells have an intrinsic property of slow proliferation.
The PI3K-AKT pathway promotes cell proliferation. Our observa-
tion that sphere cells proliferate slowly indicates that this pathway is
not highly activated in sphere cells. To test this possibility, we brieﬂy
cultured sphere cells in CM for 18 hours and then examined for
serum-induced AKT activation side-by-side with monolayer DU145
cells (Fig. 7B). It is clear that serum induces more robust AKTactivation in DU145 monolayer cells than in sphere cells (Fig. 7B),
demonstrating that DU145 stem-like cells do not display enhanced
activation of the PI3K-AKT pathway compared to monolayer DU145
cells. Consistent with this concept, sphere cells do not express
reduced levels of PTEN compared to the monolayer cells (Fig. 7B).
Since PTEN is the dominant PIP3 phosphatase, the aforementioned
observation thus supports the notion that DU145 stem-like cells do
not have their PI3K-AKT pathway activation elevated. As DU145
sphere cells proliferate more actively than monolayer cells in
sphere-forming medium observed by others [20] and ourselves
(Fig. 1D) and has been reported to display enhanced activation of
the PI3K-AKT pathway in sphere-forming medium [20], we
compared phosphorylation of Ser 473 of human AKT, a widely
used surrogate marker of AKT activation, in both monolayer and
sphere cells that were cultured in sphere-forming medium. When
cultured in this medium side-by-side for 24 and 48 hours, sphere
cells display signiﬁcantly reduced levels of AKT activation compared
to monolayer cells (Fig. 7C). Taken together, the above observations
reveal that DU145 sphere cells do not demonstrate elevated
activation of the PI3K-AKT pathway.
To further consolidate this notion, we stably knocked down
PTEN in monolayer cells using our pRIH retroviral system [21]. As
expected, knockdown of PTEN enhances AKT activation (Fig. 8A). In
comparison to empty vector (EV) retrovirus infected cells, knock-
down of PTEN did not enhance the rate of primary sphere formation
when cells were seeded at two sub-clonal densities (Fig. 8B).
Furthermore, we demonstrated that while PTEN remained knocked-
down in PTEN shRNA spheres (Fig. 8A), formation of secondary
spheres was not enhanced compared to EV spheres (Fig. 8C),
Fig. 7. DU145 sphere cells proliferate at a reduced rate with reduced levels of activation
of the PI3K-AKT pathway. A) DU145 monolayer and sphere cells were seeded at a
density of 1000 cells/well (96 well) in triplicate in CM. Cell proliferation was measured
using the MTT assay at the indicated days. Representative results (mean±SE) of three
experiments are shown. ⁎pb0.05 (two-tailed, independent t-test). B) DU145
monolayer and sphere cells were plated in serum-supplemented media for 18 hours,
followed by serum-starvation for 3 hours and then stimulating with indicated doses of
serum for 1 hour. AKT activation (phophorylation of Ser 473, AKT-P), total AKT, PTEN,
and actin expression was determined using western blot. AKT-P was quantiﬁed by ﬁrst
normalizing AKT against the respective actin and then normalizing AKT-P against the
normalized total AKT. PTEN was quantiﬁed against the respective actin. Levels of AKT-P
and PTEN were presented under the AKT-P and PTEN panels, respectively. Quantiﬁ-
cation was performed using the Scion Image software on scanned western blot images.
C) DU145 monolayer (M) and sphere (S) cells were cultured in our sphere-forming
medium for the indicated duration, followed by examination of AKT Ser 473
phosphorylation (AKT-P), total AKT, and actin by western blot using speciﬁc antibodies.
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maintaining DU145 PCSCs. Taken together, the above observations
clearly support the notion that enhanced activation of the PI3K-AKT
pathway does not play a major role in the formation and
propagation of DU145 sphere cells.
3.6. DU145 spheres display enhanced ability to form xenograft tumors in
NOD/SCID mice
CSCs are associated with signiﬁcantly enhanced tumorigenicity. To
examine whether DU145 sphere cells (stem-like cells) possess
enhanced capacity of tumorigenesis, we seeded monolayer and
sphere cells in soft agar under SFM (without addition of growth
factors), SFM+EGF, or CM media (Fig. 9). In SFM, sphere cells
produced signiﬁcantly more numbers and larger colonies than
monolayer cells (Fig. 9A, B). Even in CMmedium, althoughmonolayercells generated more colonies than sphere cells (Fig. 9A), they were
substantially smaller in size (Fig. 9B). Interestingly, sphere cells grew
as efﬁciently in SFM as in SFM+EGF in soft agar (Fig. 9A), which
further supports our observation that sphere cells have autocrine
capacity. Taken together, the above observations reveal that sphere
cells grow much more efﬁciently under an anchorage-independent
environment compared to monolayer cells, indicative of sphere cells
having enhanced capacity for tumorigenesis.
To further consolidate this concept, we performed the “gold
standard” experiment to examine the ability of DU145 sphere cells to
form tumors in NOD/SCIDmice.Wewere able to show that 105 DU145
monolayer cells generated tumors efﬁciently in NOD/SCID mice
(Fig. 9C), which is consistent with previous reports [38], and that
100 sphere cells efﬁciently produced xenograft tumors in NOD/SCID
mice (Fig. 9C). In comparison to monolayer cells, sphere cells
exhibited a 100-fold increase in tumor formation in NOD/SCID mice,
as 103, 104, and 105 sphere cells generated xenograft tumors as
efﬁcient as 105, 106, and 107 monolayer cells, respectively (Fig. 9C).
This agrees well with our observation that 1.25% of monolayer cells
formed spheres in SFM+EGF (Fig. 1C). Taken together, we demon-
strate that sphere cells have enhanced tumor-initiating capacity
compared to monolayer cells.
4. Discussion
Research on PCSCs is the focal point, not only in our understanding
of PC tumorigenesis but also in the development of new therapeutic
options to control PC [39–41]. The hedgehog pathway, a well known
pathway stimulating PC growth, is activated in PCSCs [42]. Despite
being heavily investigated, bona-ﬁde PCSCs have not been identiﬁed
and isolated from primary PCs. While PC cells with CSC properties
have been previously demonstrated [16–19,38], the majority of these
cells are unlikely to be PCSCs. This is largely due to the fact that these
cells (CD44+ or PC cells ectopically expressing hTERT) consisted of a
much larger proportion of the respective cell populations than would
be expected for PCSCs [16–19,38]. While CD133+CD44+ cells consist
of approximately 1% of monolayer DU145 cells and are enriched to
12.2% in primary spheres [20], these cells have not been thoroughly
characterized and whether they can be maintained long-term in SFM
supplemented with 20 ng/ml EGF and 20 ng/ml bFGF was not clear
[20].
We provide here a systematic investigation of sphere-propagating
cells that are derived from DU145 monolayer cell cultures. Although
bFGF has been widely used in culturing stem-like PC cells [16,20], we
showed that bFGF inhibits the generation and propagation of DU145
spheres. Using bFGF in culturing stem-like PC cells may have been
attributed to the lack of long-term maintenance of these cells in
published reports. However, we cannot exclude the possibility that
our observed inhibition of bFGF on PC sphere formation and
propagation is speciﬁc for DU145 cell-derived spheres. Although
EGF stimulates sphere generation and propagation, addition of EGF is
not required (Fig. 6). By using monolayer and sphere-derived
adherent cells (SDACs), we were able to produce spheres at different
cell densities ranged from 1 cell/μl, 5 cell/μl, and 10 cell/μl (Fig. 6).
However, we can not distinguish whether this autocrine-induced
effect is attributable to EGF or EGF-mediated autocrine signaling of
other growth factors.
Approximately 1.25% of monolayer DU145 cells are able to
generate spheres in SFM+EGF and this population is enriched to
26.2±2% in spheres. This is consistent with the percentage of well-
characterized neuronal sphere cells and brain cancer stem (sphere)
cells [9,28], and also consistent with the consensus that spheres
contain both stem and progenitor cells.
The notion that our spheres display stem-like properties is based
on the following observations: 1) Sphere-generating cells in the
monolayer cell population are enriched from 1.25% to 26.2±2% in
Fig. 8. Elevated activation of the PI3K-AKT pathway is not required for the generation and passage of DU145 spheres. A) DU145 monolayer cells were infected with an empty vector
(EV) or shPTEN retrovirus, followed by generation of spheres from these lines. AKT activation (AKT-P), total AKT, PTEN, and actin in these cells were determined by western blot.
Quantiﬁcationwas performed as described in Fig. 6 legend. * indicates AKT-P band. B) Primary spheres were generated using 24-well plates from EV and shPTEN cells at the indicated
density (b 10 cell/μl, the clonal density). Experiments were repeated three times. (C) Generation of secondary spheres from primary EV and shPTEN spheres.
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heterogeneous cell population, which can be deﬁned by the proﬁle
of cell surface and prostate lineage-speciﬁc markers in vitro (CD44,
CD24, CK18 and integrin α2β1) (Fig. 4, Supplementary Fig. 5) and
in xenograft tumors (CD44 and 34βE12) (Fig. 5); 3) Spheres could
be regenerated from these heterogeneous cell populations that were
produced by culturing in vitro in the presence of 10% FCS and in
vivo (xenograft tumors) (Fig. 3); 4) Sphere cells initiate xenograft
tumors with substantially enhanced ability in comparison to
monolayer cells (Fig. 9C); 5) In line with the above observation,
sphere cell-derived xenograft tumors might be more advanced than
monolayer cell-derived xenograft tumors. This is based on the
observations that the former contain more CD44+ cells than the
latter (Fig. 5) and that CD44+ DU145 cells have been reported to be
more tumorigenic compared to DU145 CD44- cells [19].
The observation that DU145 sphere cells are CD44+CD24+ further
suggests that these cells mark both PC progenitor and stem cell
populations. Our results are in line with reports that CD44+ PC cells
were more tumorigenic than CD44- PC cells [19]. Consistent with a
report [18], our sphere cells are CK18+. The observation that sphere
cells express both prostate basal (CD44, integrin α2β1, 34βE12+)
and luminal epithelial cell (CK18) markers suggests that these stem-
like cancer cells were generated via abnormalities that occurred
during the differentiation of a prostate stem/progenitor cell.
Although PC cells with enhanced tumor-initiating ability have been
shown to be CD133+ [16,18,20], evidence also exists that CD133+
DU145 cells are not more tumorigenic than CD133- cells [43]. Thiswould functionally support our observation that DU145 sphere cells
are not CD133-positive. Alternatively, our inability to detect CD133
might be caused by our cell culture condition. Since CD133
(prominin-1) is commonly referred as AC133, a speciﬁc glycosylated
epitope [44,45], our culture conditions may prevent this post-
translational modiﬁcation. Furthermore, the differences between
our observed and published results regarding CD133 expression in
PCSCs may be attributable to the low speciﬁcity of anti-CD133
antibodies. While the AC133 epitope of prominin-1 (CD133) is
largely associated with stem cells, the protein itself is widely
expressed in differentiated cells [45]. During the differentiation of
colon cancer stem cells, the AC133 epitope, but not the CD133
protein, is speciﬁcally reduced [46]. CD133 can be detected by several
monoclonal antibodies, including AC133. These antibodies have been
reported to recognized different CD133 epitopes [47]. Other than
AC133, whether other CD133 epitopes associate with the stem cell
population remains to be determined [47]. Although the AC133
antibody that recognizes the AC133 epitopewas used in our research,
this antibody may or may not detect other glycosylated forms of
CD133 [46].
It has recently been reported that the PI3K-AKT pathway is
activated in DU145 sphere cells and high levels of PI3K-AKT activity
are essential for the generation and maintenance of DU145 spheres or
the stem-like cell population [20]. Our research, however, is
inconsistent with their observations. We have demonstrated, from a
variety of perspectives, that DU145 stem-like cells display an
intrinsically reduced activation of the PI3K-AKT pathway. This
Fig. 9. DU145 sphere cells display enhanced tumorigenic ability. 104 DU145 sphere or monolayer cells were seeded in soft agar in 6-well plates in serum-free medium without the
addition of growth factor (−GF) or with the addition of EGF (10 ng/ml), and in DMEM/F12 media supplemented with 10% FBS. Cell colonies were formed after 8-weeks in soft agar.
The number (A) of colonies in 5 ﬁelds was determined, and the area (B) of the colonies was analyzed using ImagePro Plus 5.0 software. Similar results were obtained when cells were
seeded at 2×104 cells/well (data not shown). ⁎pb0.05 (two-tailed, independent t-test). C) The indicatedmonolayer and sphere cells were subcutaneously implanted into both ﬂanks
of NOD/SCIDmice at the indicated cell numbers. Tumor incidence (number of tumors formed/number of implantations) and tumor volume (mm3) at time of sacriﬁce (day 57 for 107
monolayer cells and day 71 for the rest of cell doses) are indicated. Mean tumor volume±standard error (SE) at time of sacriﬁce is also indicated.
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them to proliferate slowly. Additional evidence supporting this
possibility is our observation that sphere cells express very high
levels of p16INK4A exclusively in their nuclei (Supplementary Fig. 6).
Although p16INK4A is mutated in DU145 cells [48], its high level
expression in sphere cells supports the concept that sphere cells are
operating at a slow proliferative rate. Our observation that sphere
cells are in a quiescent-like environment is consistent with stem cells
being quiescent or cycling slowly in their niches [49]. The discre-
pancies between our research and the results of Dubrovska et al. may
be attributable to different cell populations being investigated. As
their cells were maintained in a high level of bFGF, their cultures
might be predominantly composed of heavily proliferating progenitor
cells. These cells would be expected to have the activated PI3K-AKT
pathway. Our observation that DU145 sphere cells proliferate slowly
is consistent with a recent report showing that CD24+ CSC cells
proliferate slower than the CD24- population [50].
Nonetheless, our research outlines a condition for long-term
culture of DU145 stem-like cells. This system will be very useful for
the investigation of unique properties of PC stem-like cells in terms of
their biology and their speciﬁc cell surface marker expression that
distinguishes them from normal prostate stem cells. Regarding
speciﬁc surface markers that are associated with stem-like cells, our
current understanding is that potential PCSCs are CD44+α2β1hiCD133+[16–18,51]. As we have shown that majority of DU145 sphere cells,
which were prepared by section of embedded spheres, are positive
for CD44, CD24, and integrin α2β1 (Fig. 2), it is thus very likely that
CD44+CD24+ α2β1+ cells are progenitors as well. Therefore, bona-
ﬁde PCSC surface markers remain to be identiﬁed. Our system will
provide a unique opportunity to identify these markers.
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